Effect of weight reduction following bariatric surgery on serum visfatin and adiponectin levels in morbidly obese subjects

Obesity Facts

Volumn 6, Issue 2, 2013, Pages 193-202

  Hosseinzadeh Attar, Mohammad Javad ^a   Golpaie, Atefeh ^a   Janani, Leila ^a   Derakhshanian, Hoda ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adiponectin; Bariatric surgery; Morbid obesity; Visfatin; Weight loss

Indexed keywords

ADIPONECTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TRIACYLGLYCEROL; GLUCOSE; INSULIN;

ADIPONECTIN BLOOD LEVEL; ADOLESCENT; ADULT; ANTHROPOMETRY; ARTICLE; BARIATRIC SURGERY; BIOCHEMICAL COMPOSITION; BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MALE; MORBID OBESITY; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE BLOOD LEVEL; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT REDUCTION; ANTHROPOMETRIC PARAMETERS; METABOLIC PARAMETERS; PROTEIN BLOOD LEVEL;

ADIPONECTIN; ADULT; BARIATRIC SURGERY; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; MALE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY, MORBID; TRIGLYCERIDES; WEIGHT LOSS; YOUNG ADULT;

EID: 84877290100     PISSN: 16624025     EISSN: 16624033     Source Type: Journal    
DOI: 10.1159/000351162     Document Type: Article

References (71)

1. Pickup J, Crook M: Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41: 1241-1248. (Pubitemid 28449093)
2. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C: Definition of metabolic syndrome report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation 2004; 109: 433-438. (Pubitemid 38133916)
3. Trujillo ME, Scherer PE: Adipose tissue-derived factors: Impact on health and disease. Endocr Rev 2006; 27: 762-778. (Pubitemid 44936059)
4. Ronti T, Lupattelli G, Mannarino E: The endocrine function of adipose tissue: An update. Clin Endocrinol 2006; 64: 355-365.
5. Shah M, Simha V, Garg A: Long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status. J Clin Endocrinol Metab 2006; 91: 4223-4231. (Pubitemid 44833388)
6. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al: Bariatric surgery. JAMA 2004; 292: 1724-1737.
7. Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, et al: Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752. (Pubitemid 47295641)
8. Ahima RS, Flier JS: Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11: 327-332.
9. Scherer PE: Adipose tissue. Diabetes 2006; 55: 1537-1545.
10. Trayhurn P: Endocrine and signalling role of adipose tissue: New perspectives on fat. Acta Physiol Scand 2005; 184: 285-293. (Pubitemid 41039735)
11. Maury E, Brichard S: Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010; 314: 1-16.
12. Faraj M, Havel PJ, Phélis S, Blank D, Sniderman AD, Cianflone K: Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003; 88: 1594-1602. (Pubitemid 36623375)
13. Ouchi N, Parker JL, Lugus JJ, Walsh K: Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11: 85-97.
14. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al: Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430. Retraction in Science 2007; 318: 565. (Pubitemid 40139988)
15. Revollo JR, Grimm AA, Imai S: The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 2007; 23: 164-170. (Pubitemid 46192971)
16. Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, et al: Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 2008; 3:e2267.
17. Guzik T, Mangalat D, Korbut R: Adipocytokines-novel link between inflammation? J Physiol Pharmacol 2006; 57: 505-528.
18. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al: Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-1758. (Pubitemid 46154646)
19. Vázquez-Vela MEF, Torres N, Tovar AR: White adipose tissue as endocrine organ and its role in obesity. Arch Med Res 2008; 39: 715-728.
20. Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, Lee MJ, et al: Human visfatin expression: Relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab 2007; 92: 666-672.
21. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B: Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006; 91: 1578-1581.
22. Ünlütürk U, Harmanci A, Yildiz BO, Bayraktar M: Dynamics of Nampt/visfatin and high molecular weight adiponectin in response to oral glucose load in obese and lean women. Clin Endocrinol 2010; 72: 469-474.
23. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, Kocelak P, Semik-Grabarczyk E, Holecki M, et al: Serum concentration of visfatin in obese women. Metabolism 2007; 56: 1131-1134. (Pubitemid 47021180)
24. Davutoglu M, Ozkaya M, Guler E, Garipardic M, Gursoy H, Karabiber H, et al: Plasma visfatin concentrations in childhood obesity: Relationships to insulin resistance and anthropometric indices. Swiss Med Weekly 2010; 139: 22.
25. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, et al: Reduced plasma visfatin/pre-B cell colonyenhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006; 91: 3165-3170. (Pubitemid 44271773)
26. Mercader J, Granados N, Caimari A, Oliver P, Bonet M, Palou A: Retinol-binding protein 4 and nicotinamide phosphoribosyltransferase/visfatin in rat obesity models. Horm Metab Res 2008; 40: 467-472.
27. Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Silva C, Rotellar F, et al: Association of increased visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity. Nutr Metab Cardiovasc Dis 2011; 21: 245-253.
28. Klöting N, Klöting I: Visfatin: Gene expression in isolated adipocytes and sequence analysis in obese WOKW rats compared with lean control rats. Biochem Biophys Res Commun 2005; 332: 1070-1072. (Pubitemid 40798194)
29. Stofkova A, Skurlova M, Kiss A, Zelezna B, Zorad S, Jurcovicova J: Activation of hypothalamic NPY, AgRP, MC4R, AND IL-6 mRNA levels in young Lewis rats with early-life diet-induced obesity. Endocr Regul 2009; 43: 99-106.
30. Krzyzanowska K, Mittermayer F, Krugluger W, Kopp HP, Schernthaner G: Increase in visfatin after weight loss induced by gastroplastic surgery. Obesity (Silver Spring) 2006; 14: 1886-1889. (Pubitemid 46121917)
31. Manco M, Fernandez-Real JM, Equitani F, Vendrell J, Mora MEV, Nanni G, et al: Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab 2007; 92: 483-490.
32. Stofkova A: Resistin and visfatin: Regulators of insulin sensitivity, inflammation and immunity. Endocr Regul 2010; 44: 25-36.
33. Kovacikova M, Vitkova M, Klimcáková E, Polak J, Hejnová J, Bajzova M, et al: Visfatin expression in subcutaneous adipose tissue of pre-menopausal women: Relation to hormones and weight reduction. Eur J Clin Invest 2008; 38: 516-522. (Pubitemid 351832035)
34. Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, et al: Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-2916. (Pubitemid 41401086)
35. Butner KL, Nickols-Richardson SM, Clark SF, Ramp WK, Herbert WG: A review of weight loss following Rouxen-Y gastric bypass vs restrictive bariatric surgery: Impact on adiponectin and insulin. Obes Surg 2010; 20: 559-568.
36. Tilg H, Hotamisligil GS: Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006; 131: 934-945. (Pubitemid 44307061)
37. Guldstrand M, Ahrén B, Adamson U: Improved β-cell function after standardized weight reduction in severely obese subjects. Am J Physiol Endocrinol Metab 2003; 284:E557-E565. (Pubitemid 36237544)
38. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, et al: Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003; 52: 239-243. (Pubitemid 36173174)
39. Stofkova A: Leptin and adiponectin: From energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul 2009; 43: 157-168.
40. Ballantyne GH, Gumbs A, Modlin IM: Changes in insulin resistance following bariatric surgery and the adipoinsular axis: Role of the adipocytokines, leptin, adiponectin and resistin. Obes Surg 2005; 15: 692-699. (Pubitemid 40847960)
41. Yermilov I, McGory ML, Shekelle PW, Ko CY, Maggard MA: Appropriateness criteria for bariatric surgery: Beyond the NIH guidelines. Obesity (Silver Spring). 2009; 17: 1521-1577.
42. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R: Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419. (Pubitemid 15018832)
43. Cottam DR, Mattar SG, Barinas-Mitchell E, Eid G, Kuller L, Kelley DE, et al: The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: Implications and effects of weight loss. Obes Surg 2004; 14: 589-600. (Pubitemid 38716577)
44. Botella-Carretero JI, Luque-Ramírez M, Álvarez-Blasco F, Peromingo R, San Millán JL, Escobar-Morreale HF: The increase in serum visfatin after bariatric surgery in morbidly obese women is modulated by weight loss, waist circumference, and presence or absence of diabetes before surgery. Obes Surg 2008; 18: 1000-1006.
45. García-Fuentes E, García-Almeida JM, García- Arnés J, García-Serrano S, Rivas-Marín J, Gallego-Perales JL, et al: Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass. Obesity (Silver Spring) 2007; 15: 2391-2395. (Pubitemid 350034032)
46. Moschen AR, Molnar C, Wolf AM, Weiss H, Graziadei I, Kaser S, et al: Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol 2009; 51: 765-777.
47. de Luis DA, Gonzalez Sagrado M, Conde R, Aller R, Izaola O, Romero E: Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients. Nutrition 2008; 24: 517-521.
48. Swarbrick M, Stanhope K, Austrheim-Smith I, Van Loan M, Ali M, Wolfe B, et al: Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. Diabetologia 2008; 51: 1901-1911.
49. de Luis DA, Izaola O, Conde R, Primo D, Sagrado MG, Aller R: Visfatin levels in female, morbid, nondiabetic obese patients after biliopancreatic diversion surgery. Surg Obes Relat Dis 2011; 7: 195-198.
50. Fernández-Real JM, Moreno JM, Chico B, López-Bermejo A, Ricart W: Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance. Diabetes Care 2007; 30: 616-621. (Pubitemid 46354343)
51. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T: Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007; 56: 451-458. (Pubitemid 46427838)
52. Golpaie A, Tajik N, Masoudkabir F, Karbaschian Z, Talebpour M, Hoseini M, et al: Short-term effect of weight loss through restrictive bariatric surgery on serum levels of vaspin in morbidly obese subjects. Eur Cytokine Netw 2011; 22: 181-186.
53. Pontiroli AE, Pizzocri P, Librenti MC, Vedani P, Marchi M, Cucchi E, et al: Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: A three-year study. J Clin Endocrinol Metab 2002; 87: 3555-3561. (Pubitemid 34879496)
54. Körner A, Garten A, Blüher M, Tauscher R, Kratzsch J, Kiess W: Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007; 92: 4783-4791. (Pubitemid 350223461)
55. Bełtowski J: Adiponectin and resistin-new hormones of white adipose tissue. Med Sci Monit 2003; 9:RA55-61. (Pubitemid 36330378)
56. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295. (Pubitemid 35373562)
57. de Carvalho CP, Marin DM, de Souza AL, Pareja JC, Chaim EA, de Barros Mazon S, et al: GLP-1 and adiponectin: Effect of weight loss after dietary restriction and gastric bypass in morbidly obese patients with normal and abnormal glucose metabolism. Obes Surg 2009; 19: 313-320.
58. Kotidis EV, Koliakos GG, Baltzopoulos VG, Ioannidis KN, Yovos JG, Papavramidis ST: Serum ghrelin, leptin and adiponectin levels before and after weight loss: Comparison of three methods of treatment-a prospective study. Obes Surg 2006; 16: 1425-1432. (Pubitemid 44759973)
59. Mari A, Manco M, Guidone C, Nanni G, Castagneto M, Mingrone G, et al: Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: Role of insulin sensitivity and beta cell function. Diabetologia 2006; 49: 2136-2143. (Pubitemid 44168482)
60. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, et al: Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women. JAMA 2003; 289: 1799-1804. (Pubitemid 37430249)
61. Abbasi F, Lamendola C, McLaughlin T, Hayden J, Reaven GM, Reaven PD: Plasma adiponectin concentrations do not increase in association with moderate weight loss in insulin-resistant, obese women. Metabolism 2004; 53: 280-283. (Pubitemid 38684685)
62. Swarbrick M, Austrheim-Smith I, Stanhope K, Van Loan M, Ali M, Wolfe B, et al: Circulating concentrations of high-molecular-weight adiponectin are increased following Roux-en-Y gastric bypass surgery. Diabetologia 2006; 49: 2552-2558. (Pubitemid 44559522)
63. Linscheid P, Christ-Crain M, Stoeckli R, Reusch C, Lutz T, Müller B, et al: Increase in high molecular weight adiponectin by bariatric surgery-induced weight loss. Diabetes Obes Metab 2008; 10: 1266-1270.
64. Vilarrasa N, Vendrell J, Sánchez-Santos R, Broch M, Megia A, Masdevall C, et al: Effect of weight loss induced by gastric bypass on proinflammatory interleukin-18, soluble tumour necrosis factor-α receptors, C-reactive protein and adiponectin in morbidly obese patients. Clin Endocrinol 2007; 67: 679-686. (Pubitemid 47628468)
65. Poitou C, Lacorte JM, Coupaye M, Bertrais S, Bedel JF, Lafon N, et al: Relationship between single nucleotide polymorphisms in leptin, IL6 and adiponectin genes and their circulating product in morbidly obese subjects before and after gastric banding surgery. Obes Surg 2005; 15: 11-23. (Pubitemid 40203820)
66. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al: Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935. (Pubitemid 32472900)
67. Antuna-Puente B, Feve B, Fellahi S, Bastard JP: Adipokines: The missing link between insulin resistance and obesity. Diabetes Metab 2008; 34: 2-11.
68. Esposito K, Giugliano G, Scuderi N, Giugliano D: Role of adipokines in the obesity-inflammation relationship: The effect of fat removal. Plast Reconstr Surg 2006; 118: 1048-1057. (Pubitemid 44412941)
69. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, et al: Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007; 76: 24-29. (Pubitemid 46240362)
70. Retnakaran R, Youn BS, Liu Y, Hanley AJG, Lee NS, Park JW, et al: Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: A cross-sectional study. Clin Endocrinol 2008; 69: 885-893.
71. Benedix F, Westphal S, Patschke R, Granowski D, Luley C, Lippert H, et al: Weight loss and changes in salivary ghrelin and adiponectin: Comparison between sleeve gastrectomy and Roux-en-Y gastric bypass and gastric banding. Obes Surg 2011; 21: 616-624.